(Q35589197)

9 August 2017

Weekly paclitaxel infusion as salvage therapy in ovarian cancer (English)

1 reference

9 August 2017

1 reference

David M Boruta

1

1 reference

9 August 2017

Wesley C Fowler

2

1 reference

9 August 2017

Paola A Gehrig

3

1 reference

9 August 2017

John F Boggess

4

1 reference

9 August 2017

Leslie A Walton

5

1 reference

9 August 2017

Linda Van Le

6

1 reference

9 August 2017

1 January 2003

1 reference

9 August 2017

1 reference

9 August 2017

21

1 reference

9 August 2017

5

1 reference

9 August 2017

675-681

1 reference

9 August 2017

Cancer statistics, 2000.

1 reference

https://api.crossref.org/works/10.1081%2FCNV-120023765

Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1081%2FCNV-120023765

Second-line treatment of ovarian cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1081%2FCNV-120023765

Taxol: a novel investigational antimicrotubule agent

21 January 2018

1 reference

https://api.crossref.org/works/10.1081%2FCNV-120023765

Paclitaxel for platinum-refractory ovarian cancer: results from the first 1,000 patients registered to National Cancer Institute Treatment Referral Center 9103.

21 January 2018

1 reference

https://api.crossref.org/works/10.1081%2FCNV-120023765

Phase II trial of paclitaxel in patients with progressive ovarian carcinoma after platinum-based chemotherapy: a Gynecologic Oncology Group study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1081%2FCNV-120023765

Long-term results from a phase II study of single agent paclitaxel (Taxol) in previously platinum treated patients with advanced ovarian cancer: the Nordic experience.

21 January 2018

1 reference

https://api.crossref.org/works/10.1081%2FCNV-120023765

Treatment of relapsed carcinoma of the ovary with single-agent paclitaxel following exposure to paclitaxel and platinum employed as initial therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1081%2FCNV-120023765

Phase II study of liposomal doxorubicin in refractory ovarian cancer: antitumor activity and toxicity modification by liposomal encapsulation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1081%2FCNV-120023765

Topotecan, an active drug in the second-line treatment of epithelial ovarian cancer: results of a large European phase II study

21 January 2018

1 reference

https://api.crossref.org/works/10.1081%2FCNV-120023765

Prolonged oral etoposide as second-line therapy for platinum-resistant and platinum-sensitive ovarian carcinoma: a Gynecologic Oncology Group study

21 January 2018

1 reference

https://api.crossref.org/works/10.1081%2FCNV-120023765

Altretamine (hexamethylmelamine) in platinum-resistant and platinum-refractory ovarian cancer: a Gynecologic Oncology Group phase II trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1081%2FCNV-120023765

Tamoxifen in platinum-refractory ovarian cancer: a Gynecologic Oncology Group Ancillary Report

21 January 2018

1 reference

https://api.crossref.org/works/10.1081%2FCNV-120023765

Dose-dense therapy with weekly 1-hour paclitaxel infusions in the treatment of metastatic breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1081%2FCNV-120023765

Paclitaxel (Taxol): an inhibitor of angiogenesis in a highly vascularized transgenic breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1081%2FCNV-120023765

Activity of Gemcitabine in Patients with Advanced Ovarian Cancer: Responses Seen Following Platinum and Paclitaxel

21 January 2018

1 reference

https://api.crossref.org/works/10.1081%2FCNV-120023765

21 January 2018

1 reference

https://api.crossref.org/works/10.1081%2FCNV-120023765

Phase I and pharmacologic study of paclitaxel administered weekly in patients with relapsed ovarian cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1081%2FCNV-120023765

Defining response of ovarian carcinoma to initial chemotherapy according to serum CA 125

21 January 2018

1 reference

https://api.crossref.org/works/10.1081%2FCNV-120023765

Paclitaxel as salvage therapy in advanced pretreated ovarian cancer: a phase II study

21 January 2018

1 reference

https://api.crossref.org/works/10.1081%2FCNV-120023765

Paclitaxel (Taxol) monotherapy in the treatment of progressive and recurrent ovarian carcinoma after platinum-based chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1081%2FCNV-120023765

Taxol as second-line treatment in patients with advanced ovarian cancer after platinum-based first-line chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1081%2FCNV-120023765

21 January 2018

Identifiers

DOI

10.1081/CNV-120023765

1 reference

9 August 2017

1 reference